133 related articles for article (PubMed ID: 38327192)
21. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer.
Freed-Pastor WA; Lambert LJ; Ely ZA; Pattada NB; Bhutkar A; Eng G; Mercer KL; Garcia AP; Lin L; Rideout WM; Hwang WL; Schenkel JM; Jaeger AM; Bronson RT; Westcott PMK; Hether TD; Divakar P; Reeves JW; Deshpande V; Delorey T; Phillips D; Yilmaz OH; Regev A; Jacks T
Cancer Cell; 2021 Oct; 39(10):1342-1360.e14. PubMed ID: 34358448
[TBL] [Abstract][Full Text] [Related]
22. CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer.
Piro G; Carbone C; Agostini A; Esposito A; De Pizzol M; Novelli R; Allegretti M; Aramini A; Caggiano A; Granitto A; De Sanctis F; Ugel S; Corbo V; Martini M; Lawlor RT; Scarpa A; Tortora G
Br J Cancer; 2023 Jan; 128(2):331-341. PubMed ID: 36385556
[TBL] [Abstract][Full Text] [Related]
23. A "bulldozer" driven by anoxic bacteria for pancreatic cancer chemo-immunotherapy.
Zhang H; Wang Y; Zhu L; Qi Z; Cao K; Chang J; Hou L
J Control Release; 2023 Aug; 360():660-671. PubMed ID: 37433371
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response.
Taylor BC; Balko JM
Front Immunol; 2022; 13():844866. PubMed ID: 35296095
[TBL] [Abstract][Full Text] [Related]
25. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
26. Nano-Econazole Enhanced PD-L1 Checkpoint Blockade for Synergistic Antitumor Immunotherapy against Pancreatic Ductal Adenocarcinoma.
Li Q; Qin S; Tian H; Liu R; Qiao L; Liu S; Li B; Yang M; Shi J; Nice EC; Li J; Lang T; Huang C
Small; 2023 Jun; 19(23):e2207201. PubMed ID: 36899444
[TBL] [Abstract][Full Text] [Related]
27. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy and Prevention of Pancreatic Cancer.
Morrison AH; Byrne KT; Vonderheide RH
Trends Cancer; 2018 Jun; 4(6):418-428. PubMed ID: 29860986
[TBL] [Abstract][Full Text] [Related]
29. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis.
Ho TTB; Nasti A; Seki A; Komura T; Inui H; Kozaka T; Kitamura Y; Shiba K; Yamashita T; Yamashita T; Mizukoshi E; Kawaguchi K; Wada T; Honda M; Kaneko S; Sakai Y
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33188035
[TBL] [Abstract][Full Text] [Related]
30. Un-FASN-ing cancer's seat belt: Linking lipid metabolism and antigen presentation.
Corey Z; Schechter E; Nemenoff RA
Cell Chem Biol; 2023 Sep; 30(9):1004-1006. PubMed ID: 37738950
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of immune evasion in breast cancer.
Bates JP; Derakhshandeh R; Jones L; Webb TJ
BMC Cancer; 2018 May; 18(1):556. PubMed ID: 29751789
[TBL] [Abstract][Full Text] [Related]
32. Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway.
Pu N; Gao S; Yin H; Li JA; Wu W; Fang Y; Zhang L; Rong Y; Xu X; Wang D; Kuang T; Jin D; Yu J; Lou W
Cancer Lett; 2019 Sep; 460():42-53. PubMed ID: 31233838
[TBL] [Abstract][Full Text] [Related]
33. Acquired resistance to immunotherapy in MMR-D pancreatic cancer.
Hu ZI; Hellmann MD; Wolchok JD; Vyas M; Shia J; Stadler ZK; Diaz LA; O'Reilly EM
J Immunother Cancer; 2018 Nov; 6(1):127. PubMed ID: 30458888
[TBL] [Abstract][Full Text] [Related]
34. Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC).
Chen H; Yang G; Xiao J; Zheng L; You L; Zhang T
Cancer Lett; 2020 Oct; 490():12-19. PubMed ID: 32590021
[TBL] [Abstract][Full Text] [Related]
35. Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance.
Ajina R; Malchiodi ZX; Fitzgerald AA; Zuo A; Wang S; Moussa M; Cooper CJ; Shen Y; Johnson QR; Parks JM; Smith JC; Catalfamo M; Fertig EJ; Jablonski SA; Weiner LM
Cancer Immunol Res; 2021 Apr; 9(4):386-400. PubMed ID: 33509790
[TBL] [Abstract][Full Text] [Related]
36. Lipid Carriers in Cancer: Context Matters.
Sherman MH
Cancer Res; 2021 Aug; 81(16):4186-4187. PubMed ID: 34400469
[TBL] [Abstract][Full Text] [Related]
37. Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression.
Zheng NN; Zhou M; Sun F; Huai MX; Zhang Y; Qu CY; Shen F; Xu LM
World J Gastroenterol; 2020 Jul; 26(26):3737-3749. PubMed ID: 32774054
[TBL] [Abstract][Full Text] [Related]
38. Bioinformatics analyses of infiltrating immune cell participation on pancreatic ductal adenocarcinoma progression and in vivo experiment of the therapeutic effect of Shuangshen granules.
Hu J; Jiang J; Xu B; Li Y; Wang B; He S; Ren X; Shi B; Zhang X; Zheng H; Hua B; Liu R
J Ethnopharmacol; 2024 Mar; 322():117590. PubMed ID: 38113986
[TBL] [Abstract][Full Text] [Related]
39. Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far.
Wong W; Alouani E; Wei A; Ryu YK; Chabot JA; Manji GA
Semin Oncol; 2021 Feb; 48(1):57-68. PubMed ID: 33965249
[TBL] [Abstract][Full Text] [Related]
40. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
Jiang H; Hegde S; Knolhoff BL; Zhu Y; Herndon JM; Meyer MA; Nywening TM; Hawkins WG; Shapiro IM; Weaver DT; Pachter JA; Wang-Gillam A; DeNardo DG
Nat Med; 2016 Aug; 22(8):851-60. PubMed ID: 27376576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]